10 February 2016

Grant of Share Options

VERONA PHARMA PLC - Grant of Share Options

PR Newswire

Verona Pharma plc

("Verona Pharma" or the "Company")

Grant of Share Options

10 February 2016, Cardiff – Verona Pharma plc (AIM: VRP) announces that the Board has on 9 February 2016 granted options over 14,900,000 ordinary shares (“Options”) in the Company to one of its Directors and certain employees in accordance with the terms of the Company’s share option plans. Half of the Options will vest on 9 February 2018 and the other half on 9 February 2019. The Options have a ten-year exercise window from the date of grant.

Of the Options granted, 10,000,000 options have been granted to Dr. Jan-Anders Karlsson, half of which have an exercise price of 4 pence per option and the other half have an exercise price of 6.6 pence per option.

Dr. Karlsson’s total beneficial interest in the Company remains 2,870,000 ordinary shares, representing 0.28% of the Company’s issued share capital. Following this grant, Dr. Karlsson holds options over 38,000,000 ordinary shares, representing 3.76% of the Company’s issued share capital, with a range of exercise prices between 2.5 and 15 pence per option.


For further information please contact:

Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer  
N+1 Singer Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer  
FTI Consulting Tel: +44 (0)20 3727 1000
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins  

Notes to Editors

About Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis.

Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase II trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting.  The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma.

Verona Pharma is also building a broader portfolio of RPL554-containing products to maximise its benefit to patients and its value.  This includes the very significant markets for COPD and asthma maintenance therapy.  The Company is also exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing and has received a Venture and Innovation Award from the Cystic Fibrosis Trust.

For further information please contact:


Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000



FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251

Stephanie Carrington
Tel. +1 646-277-1282


Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us